Volume : 09, Issue : 12, December – 2022
Title:
93.DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF SITAGLIPTIN AND METFORMIN IN BULK AND PHARMACEUTICAL DOSAGE FORMS.
Authors :
K.Pavithra, S.Saranya
Abstract :
A simple, accurate, specific and reliable RP-HPLC method for the simultaneous estimation of Sitagliptin Phosphate and Metformin Hydrochloride in Pharmaceutical dosage form was developed and validated according to currently accepted ICH guidelines of analytical method validation. In the present method, SHIMADZU HPLC with UV detector LC 10 AT VP with analytical column PHENOMENEX Luna (C18) A 100 RP Column, 250 mm x 4.6 mm x 5μm, an injection volume of 20µl was injected and eluted with mobile phase 0.02M Potassium dihydrogen phosphate pH (4.0): Acetonitrile (60:40) pumped at a flow rate of 1.0ml/min. Sitagliptin Phosphate and Metformin Hydrochloride were eluted at 2.718 and 1.925 min. The detection was carried out at a wavelength 252nm. The method was validated for system suitability, linearity, accuracy, precision and robustness of sample solution. The linear ranges for Metformin Hydrochloride and Sitagliptin Phosphate were 20-120μg/mL, 2-12μg/mL respectively with good recoveries i.e. 99.4% to 101.35%.
Keywords: Metformin Hydrochloride, Sitagliptin Phosphate, RP-HPLC.
Cite This Article:
Please cite this article in press K.Pavithra et al, Development And Validation Of RP-HPLC Method For Simultaneous Determination Of Sitagliptin And Metformin In Bulk And Pharmaceutical Dosage Forms.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
1. Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006 Aug;46(8):876-86.
2. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C: Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753-68.
3. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F: Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012 Mar;122(6):253-70.
4. Rena G, Hardie DG, Pearson ER: The mechanisms of action of metformin. Diabetologia. 2017 Sep;60(9):1577-1585.
5. Rena G, Pearson ER, Sakamoto K: Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013 Sep;56(9):1898-906.
6. Pulla PR, Sastry BS, Prasad YR, Raju NA. Simultaneous estimation of metformin HCl and sitagliptin phosphate in tablet dosage forms by RPHPLC; Res. J. Pharm. Techn. 2011; 04(04):646-50.
7. Ramzia I, Bagary E, Elkady EF, Ayoub BM. Spectroflourometric and spectrophotometric methods for the determination of sitagliptin in binary mixture with metformin and ternary mixture with metformin and sitagliptin alkaline degradation product; Int. J. Biomed. sci. 2011; 7(1): 62-9.
8. Khan G, Sahu D, Agrawal YP, Sabarwal N, Jain A, Gupta AK. Simultaneous estimation of metformin and sitagliptin in tablet dosage form; Asian. J. Biochem. Pharm. Res. 2011; 1(2): 352-8.
9. Sahoo PK, Sharma R, Chaturvedi SC. Simultaneous estimation of metformin hydrochloride and pioglitazone hydrochloride by RP-HPLC method from combined tablet dosage form; Ind. J. Pharm. Sci. 2008; 70(3): 383–6.
10. Havaldar FH, Vairal DL. Simultaneous estimation of metformin hydrochloride, rosiglitazone and pioglitazone hydrochloride in the tablets dosage form; Int. J. Appl. Biol. Pharm. Tech. 2010; 1(3):1000-5.
11. Rashid SH, Munjewar R, Farooqui M. Simultaneous determination of atenolol and metformin hydrochloride by reverse phase high performance liquid chromatography; Current Pharma. Res. 2010; 1(1): 44-8.